Sutro Biopharma STRO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Financing Component On Unearned Revenue | $911K+20.0% | $759K+17.5% | $646K-22.4% | $832K-29.3% | $1.18M+6.6% | |
| Materials Supply | $1.08M-40.0% | $1.8M-26.0% | $2.44M-56.6% | $5.62M+204% | $1.85M+74.2% | |
| Ongoing Performance Related To Unsatisfied Performance Obligations | $11.96M+81.2% | $6.6M+10.8% | $5.96M-88.2% | $50.43M+289% | $12.96M+117% | |
| Research And Development Services | $556K+29.9% | $428K-18.3% | $524K-14.0% | $609K-32.2% | $898K-2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Sutro Biopharma break its business down?
- Sutro Biopharma (STRO) reports revenue by product across 4 parts — Financing Component On Unearned Revenue, Materials Supply, Ongoing Performance Related To Unsatisfied Performance Obligations and Research And Development Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Sutro Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Sutro Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
